{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:23:44Z","timestamp":1762273424734,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006795","name":"Heart Failure Society of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartandlung.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.hrtlng.2025.04.027","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T02:28:11Z","timestamp":1746066491000},"page":"64-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical outcomes of sacubitril-valsartan versus angiotensin converting enzyme inhibitor or angiotensin receptor blocker among patients with heart failure and ejection fraction at\/less than 60\u202f%: A retrospective, observational, parallel cohort, multi-group study"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3619-966X","authenticated-orcid":false,"given":"Nancy M.","family":"Albert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James F.","family":"Bena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon L","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Bradley","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Faulkenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Khairnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trejeeve","family":"Martyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.hrtlng.2025.04.027_bib0001","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrtlng.2025.04.027_bib0002","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hrtlng.2025.04.027_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"PARAGLIDE-HF Investigators. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hrtlng.2025.04.027_bib0004","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hrtlng.2025.04.027_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.hrtlng.2025.04.027_bib0006","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3390\/jcm12020699","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction: real-world experience from Italy (the REAL.IT Study)","volume":"12","author":"Di Lenarda","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.hrtlng.2025.04.027_bib0007","doi-asserted-by":"crossref","first-page":"193","DOI":"10.36628\/ijhf.2022.0015","article-title":"Real-world usage of sacubitril\/valsartan in Korea: a multi-center, retrospective study","volume":"4","author":"Park","year":"2022","journal-title":"Int J Heart Fail"},{"issue":"31","key":"10.1016\/j.hrtlng.2025.04.027_bib0008","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.hrtlng.2025.04.027_bib0009","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/FJC.0000000000001421","article-title":"Effects of sacubitril-valsartan in patients with various types of heart failure: a meta-analysis","volume":"81","author":"Zhang","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"issue":"11","key":"10.1016\/j.hrtlng.2025.04.027_bib0010","article-title":"Comparison of outcomes between sacubitril\/valsartan and enalapril in patients with heart failure: a systematic review and meta-analysis","volume":"15","author":"Reyaz","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.hrtlng.2025.04.027_bib0011","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.hrtlng.2025.04.027_bib0012","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"issue":"6","key":"10.1016\/j.hrtlng.2025.04.027_bib0013","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"10367","key":"10.1016\/j.hrtlng.2025.04.027_bib0014","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hrtlng.2025.04.027_bib0015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/jamacardio.2023.4553","article-title":"Optimization of evidence-based heart failure medications after an acute heart failure admission: a secondary analysis of the STRONG-HF randomized clinical trial","volume":"9","author":"Cotter","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.hrtlng.2025.04.027_bib0016","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40265-023-01887-4","article-title":"Guideline-directed medical therapy for the treatment of heart failure with reduced ejection fraction","volume":"83","author":"Patel","year":"2023","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.hrtlng.2025.04.027_bib0017","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cardfail.2023.12.004","article-title":"Improving guideline-directed medical therapy for patients with heart failure with reduced ejection fraction: a review of implementation strategies","volume":"30","author":"Harrington","year":"2024","journal-title":"J Card Fail"},{"issue":"15","key":"10.1016\/j.hrtlng.2025.04.027_bib0018","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology solution set oversight committee","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hrtlng.2025.04.027_bib0019","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jama.2021.8844","article-title":"Effect of a hospital and postdischarge quality improvement intervention on clinical outcomes and quality of care for patients with heart failure with reduced ejection fraction: the connect-HF randomized clinical trial","volume":"326","author":"Devore","year":"2021","journal-title":"JAMA - J Am Med Assoc"},{"issue":"22","key":"10.1016\/j.hrtlng.2025.04.027_bib0020","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.jacc.2023.03.426","article-title":"Uptitrating treatment after heart failure hospitalization across the spectrum of left ventricular ejection fraction","volume":"81","author":"Pagnesi","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.hrtlng.2025.04.027_bib0021","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"37","key":"10.1016\/j.hrtlng.2025.04.027_bib0022","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"ESC Scientific Document Group. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.hrtlng.2025.04.027_bib0023","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC Expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.hrtlng.2025.04.027_bib0024","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/jep.13885","article-title":"Clinician challenges to evidence-based prescribing for heart failure and reduced ejection fraction: a qualitative evaluation","volume":"29","author":"Trinkley","year":"2023","journal-title":"J Eval Clin Pract"},{"issue":"3","key":"10.1016\/j.hrtlng.2025.04.027_bib0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002493","article-title":"Barriers to adoption of mineralocorticoid receptor antagonists in patients with heart failure: a mixed-methods study","volume":"5","author":"Dev","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.hrtlng.2025.04.027_bib0026","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2023.03.430","article-title":"Implementing guideline-directed medical therapy for heart failure: JACC focus seminar 1\/3","volume":"82","author":"Patolia","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrtlng.2025.04.027_bib0027","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjcard.2023.07.099","article-title":"Comparative outcomes of sacubitril\/valsartan use after hospitalization for heart failure among Medicare beneficiaries na\u00efve to renin-angiotensin system inhibitors","volume":"204","author":"Pierce","year":"2023","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.hrtlng.2025.04.027_bib0028","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jchf.2021.06.018","article-title":"Sacubitril\/Valsartan adherence and postdischarge outcomes among patients hospitalized for heart failure with reduced ejection fraction","volume":"9","author":"Carnicelli","year":"2021","journal-title":"JACC Heart Fail"}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956325000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956325000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:53:18Z","timestamp":1762246398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956325000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"alternative-id":["S0147956325000937"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2025.04.027","relation":{},"ISSN":["0147-9563"],"issn-type":[{"type":"print","value":"0147-9563"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of sacubitril-valsartan versus angiotensin converting enzyme inhibitor or angiotensin receptor blocker among patients with heart failure and ejection fraction at\/less than 60\u202f%: A retrospective, observational, parallel cohort, multi-group study","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2025.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}